CLL lab Copenhagen

Combining translational, epidemiological and clinical research to develop individually tailored supportive care and CLL specific treatment.

[Carsten Niemann @carsten_niemann]

Mulighed for at bringe personlig medicin et skridt videre - genopslag af data manager stilling i min forskningsgruppe: https://t.co/RRAfDdXL4r
@Rigshospitalet #data #datamanagement #forskning #BigData #MachineLearning

[Carsten Niemann @carsten_niemann]

Next steps introducing decission support for patients with hematological malignancies @LabCll #CLL #PrecisionMedicine https://t.co/Rlxes2EbZk

[Carsten Niemann @carsten_niemann]

Vær med til at forbedre behandlingen for vores patienter - forskningssekretær søges til vores aktive forskningsgruppe: https://t.co/TRJYh6kyMG @Rigshospitalet @LabCll

[CLL lab Copenhagen @LabCll]

Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data is now available online! https://t.co/3lI1TAcG4Y

[Carsten Niemann @carsten_niemann]

MRD-guided therapy works in CLL - proud to publish together with @ArnonPkater and co-authors the primary analysis of the VISION/HO141 trial in Lancet Oncology: https://t.co/A0Qk3WN2aB

[CLL lab Copenhagen @LabCll]

We are hiring a Data Manager at CLL lab at Rigshospitalet, Copenhagen University.
Please see the full call here: https://t.co/1pGSOVcVPW

[CLL lab Copenhagen @LabCll]

these growth rates. Using our tool in the clinic might help clinicians to decide who needs treatment for CLL and when, potentially leading to better outcomes for patients.

https://t.co/QA6K9szTgb

[CLL lab Copenhagen @LabCll]

While clinicians largely agree that patients with chronic lymphocytic leukemia (CLL) have increased levels of white blood cells in the years preceding their diagnosis, there is less certainty as to how and when this increase occurs.

[CLL lab Copenhagen @LabCll]

A better understanding of how white blood cell levels change during this period might help us to predict who will become ill and require treatment. In this work, we explore patterns of white blood cell growth and develop a tool to predict time to treatment for CLL based on ...

[Carlos Chiattone @CarlosChiattone]

Thanks to all speakers who accepted to participate in the 12st Brazilian Lymphoma Conference!

[Carsten Niemann @carsten_niemann]

For patients with CLL suffering from immunodeficiency, early antiviral therapy upon COVID-19 omicron BA.2 sublineage still seems warranted: https://t.co/10Wsw9uwtD
#CLL #COVID19 @PERSIMUNE @CLL_CLUE @ERANET_PerMed @LabCll

[CLL lab Copenhagen @LabCll]

We’re thrilled to announce the launch of Personalised Medicine from a Nordic Perspective on @coursera
Instructor:@SisseOstrowski

@carsten_niemann and Rudi Agius cover Personalised Medicine in CLL in Week 2!

Join the free online course on Coursera: https://t.co/T4FCTBB7WI

[Toby A. Eyre @tobyeyre82]

CLL12 in @BloodJournal
Langerbeins et al
Ibrutinib vs observation in high risk asymptomatic
TN Binet stage A #CLL
Significant EFS benefit (HR 0.25) for #ibrutinib

AE profile in placebo group is fascinating to see!

No OS benefit (few events to date, long fup needed) #CLL #lymsm

[Toby A. Eyre @tobyeyre82]

What is next for #pirtobrutinib in #CLL ?
Check out this trial in progress abstract
BRUIN CLL322
Recruiting globally now!
Ven-R+Loxo305 (pirtobrutinib) vs Ven-R + placebo in covalent BTKi exposed or naive R/R CLL. #ASH21

[Toby A. Eyre @tobyeyre82]

What is next for #pirtobrutinib in #MCL ?
Check out this trial in progress abstract
BRUIN MCL321
Recruiting globally now!
Loxo305 (pirtobrutinib) vs Investigator choice covalent BTKi in BTKi-naive R/R MCL. #ASH21

[Toby A. Eyre @tobyeyre82]

Hermine et al
Very long term (15y+) data for EMCLN trial
RCHOP->ASCT vs RDHAP/RCHOP -> ASCT
Nil Ritux Maintenance
Long term benefit for HD Ara-C containing arm
? plateau on curve
Are % of lower risk (low MIPI) pts functionally cured? #ASH21 #MCL #lymsm

[Mihaela van der Schaar @MihaelaVDS]

🚨OPPORTUNITY ALERT! Our lab has a handful of fully-funded positions (starting 2022) for top-tier PhD students to develop cutting-edge ML for healthcare. If you're interested, get in touch; if you know someone who might be interested, please share this! 👇
https://t.co/zfivna5xwb

[Toby A. Eyre @tobyeyre82]

Nil new in the abstract for now, but do check out the live presentation from @anthonymatomd

Updated data to include ~100 new #CLL pts (i.e. approx 270 total) treated with #pirtobrutinib and additional 10 months since the prior data cut presented.

Don't miss it! #CLL #ASH21

[ASH @ASH_hematology]

#ASH21 abstracts are now live! Click here: https://t.co/uVULxc60EN

What abstracts are you most excited about? 🤩 Tells us via quote retweets or replies!

[Toby A. Eyre @tobyeyre82]

.@mattwilson2287 et al
N=1384
1L #DLBCL RCHOP/RCHOP-like pts
Global collaboration
Intercalated HDMTX vs End of treatment HDMTX
No diff in CNS relapse rate or PFS/OS (landmark analysis)
Intercalation results in RCHOP delays
Fantastic effort
Congrats to all involved #lymsm #ASH2021